DOI 10.1016/j.jiph.2025.102987
Real-world efficacy of oral azvudine in hospitalized patients with COVID-19: A multicenter retrospective cohort study.
Аннотация
BACKGROUND
Azvudine has become a widely used treatment for COVID-19 in China. Our study aimed to assess the real-world efficacy of azvudine in hospitalized COVID-19 patients during the omicron variant surge.
METHODS
This multicenter retrospective cohort study was conducted at three hospitals, starting from December 2022. We developed a propensity-score matching (PSM) model to compare patients receiving azvudine with a control group. The primary outcome measured was a composite outcome, while secondary outcomes included all-cause death, intensive care unit admission, and initiation of invasive mechanical ventilation.
RESULTS
We enrolled a total of 7216 hospitalized COVID-19 patients, monitoring them for 28 days. Following PSM, we included 901 patients in both the azvudine group and the control group. The incidence of the composite outcome was 20.2 % in the azvudine group and 25.5 % in the control group (p = 0.007). The all-cause mortality rate was 10.0 % in the azvudine group and 13.7 % in the control group (p = 0.016). The intensive care unit admission was 15.5 % in the azvudine group and 19.6 % in the control group (p = 0.022).
CONCLUSION
During the omicron epidemic in China, oral administration of azvudine was associated with a reduced risk of the composite outcome and all-cause mortality in COVID-19 patients.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.